Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Standard Culture Versus Advanced Guidance UTI® Testing in Older Adults (SAGE UTI)

10 de novembro de 2026 atualizado por: Pathnostics

SAGE-UTI: Standard Culture Versus Advanced Guidance UTI® Testing in Older Adults: a Single-blind Randomized Controlled Trial Evaluating Outcomes in UTI

The goal of this clinical trial is to compare two urine testing methods used to diagnose urinary tract infections (UTIs) in adults aged 60 years and older.

The main question this trial aims to answer is:

Does Guidance® UTI testing, compared with standard urine culture, improve patient outcomes and help healthcare providers make more appropriate antibiotic treatment decisions?

Participants will:

  • Be randomly assigned to either Guidance UTI testing or standard urine culture testing.
  • Provide a urine sample during their initial clinic visit.
  • Complete questionnaires at the initial visit and approximately 14 and 28 days later.

Researchers will compare UTI-related repeat medical visits, emergency care, hospitalizations, new UTI diagnoses, and antibiotic treatment decisions between the two groups.

Visão geral do estudo

Descrição detalhada

**Background and Rationale**

Urinary tract infections (UTIs) are common among older adults, particularly those with recurrent infections or underlying urinary tract conditions. Standard urine culture has limitations, including delayed results, incomplete detection of certain pathogens, and challenges identifying infections involving multiple organisms. These limitations may contribute to empiric antibiotic prescribing, inappropriate treatment, and adverse clinical outcomes.

Guidance® UTI combines multiplex polymerase chain reaction (M-PCR) for microbial identification and resistance gene detection with pooled antibiotic susceptibility testing (P-AST). This approach provides microbial identification and antibiotic susceptibility results within approximately 48 hours of laboratory receipt.

**Trial Design**

SAGE-UTI is a prospective, multicenter, single-blind, randomized controlled trial comparing Guidance UTI testing with standard urine culture in adults aged 60 years and older presenting with suspected UTIs.

Following informed consent and confirmation of eligibility, participants will be randomized in a 1:1 ratio to one of two diagnostic testing pathways:

  • **Arm A - Guidance UTI:** Urine specimens will undergo molecular microbial identification and pooled antibiotic susceptibility testing.
  • **Arm B - Standard Urine Culture:** Urine specimens will undergo standard urine culture and antibiotic susceptibility testing, as available, according to routine clinical practice.

All urine specimens will be processed at the Pathnostics central laboratory. Treating clinicians will receive results corresponding to the assigned diagnostic pathway and will make antibiotic treatment decisions based on clinical judgment and routine practice. Results from the alternative testing pathway will remain blinded unless disclosure is medically necessary for participant safety or appropriate clinical management.

**Trial Procedures**

Participants will undergo a baseline clinical assessment, urine specimen collection, and documentation of relevant medical history, symptoms, and antibiotic treatment.

Treating clinicians will complete a treatment decision survey following review of the assigned diagnostic results. Participants will complete follow-up assessments at approximately Days 14 and 28 to document clinical outcomes and UTI-related healthcare utilization.

Residual urine specimens will also be evaluated for exploratory urinary biomarkers, including interleukin-1 beta (IL-1β), interleukin-8 (IL-8), and neutrophil gelatinase-associated lipocalin (NGAL), to explore their relationship with diagnostic findings and clinical outcomes. These exploratory results will not be reported to treating clinicians.

**Clinical Significance**

The trial will evaluate whether Guidance UTI testing, compared with standard urine culture, improves clinical outcomes and supports more appropriate antibiotic prescribing in older adults with suspected UTIs. The findings may help inform diagnostic testing strategies, improve UTI management, and support antimicrobial stewardship.

Tipo de estudo

Observacional

Inscrição (Estimado)

2000

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

60 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Individuals ≥ 60 years old requiring evaluation for suspected urinary tract infection, whose clinical management will be impacted by the provided results, seen in outpatient urology or urogynecology specialty practice

Descrição

nclusion Criteria:

  • Able to provide written informed consent
  • Male and female subjects ≥ 60 may participate with no predetermined quotas or ratios for gender participation.
  • A history of (at least one): a) recurrent UTIs (defined as ≥ 2 UTIs within a 6 month period in the last 12 months) b) urinary tract obstruction (including urinary retention or hydronephrosis) and/or urinary tract injury (i.e. nephrolithiasis, ureteral or urinary stent placement, or any urologic surgery or instrumented procedure) within the last 24 months
  • Must present at the time of enrollment with clinically suspected active UTI (any lower urinary tract symptoms)
  • Must have positive chemical (dipstick) urinalysis (defined as nitrite "positive" and/or leukocyte esterase > "trace" by chemical urinalysis) performed at the baseline (Day 1) visit.
  • Management requires microbial identification and antibiotic sensitivities from urine
  • Able to provide a urine specimen (midstream voided or catheter collected)

Exclusion Criteria:

  • Subjects with indwelling catheter (suprapubic or foley) or are chronically reliant on intermittent self-catheterization
  • Subjects with suspected pyelonephritis, febrile UTI, or bacteremic UTI (as indicated by one or more of the following symptoms: fever, chills, rigors, hemodynamic instability, flank pain, costovertebral angle tenderness)
  • Subjects with suspected prostatitis (presence of tender, enlarged, or boggy prostate on digital rectal examination; history of prostate biopsy or surgery in previous 30 days)
  • Currently receiving radiation therapy in the pelvic region
  • Subjects with history of unstable, untreated, or are failing treatment for overactive bladder (either neurogenic or non-neurogenic)
  • Subjects with history of bladder malignancy in the past 3 years
  • Subjects that have been treated with chemotherapy in the past 3 years
  • Inability to independently complete subject surveys (i.e. unable to read or hear survey questions and respond appropriately)
  • Incarceration
  • Pregnancy

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: OTHER
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Arm A - Guidance UTI

Urine specimens will undergo molecular microbial identification and pooled antibiotic susceptibility testing.

Arm B - Standard Urine Culture:

Urine specimens will undergo standard urine culture and antibiotic susceptibility testing, as available, according to routine clinical practice.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percent difference between diagnostic test arm in the number of composite negative outcomes
Prazo: 28 days

Percent difference between diagnostic test arm in the number of composite negative outcomes (e.g., return visit to provider for UTI, ER visit for UTI, urgent care visit for UTI, hospitalization for UTI, new UTI diagnosis)

28 days

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Percent difference between diagnostic test arm in: • The number of adverse events • The number of subjects empirically treated • The number of changes to antibiotic(s) prescribed
Prazo: 28 days

Percent difference between diagnostic test arm in:

  • The number of adverse events
  • The number of subjects empirically treated
  • The number of changes to antibiotic(s) prescribed
28 days
Differences in microbial identification, quantitation, and antibiotic susceptibility results between the two test results for the same subject
Prazo: 28 days

Differences in microbial identification, quantitation, and antibiotic susceptibility results between the two test results for the same subject

28 days
Percentage of directed antibiotic prescriptions that are concordant with susceptibility testing result(s)
Prazo: 28 days

Percentage of directed antibiotic prescriptions that are concordant with susceptibility testing result(s)

28 days
Relative frequency with which result components and other factors are reported to influence antibiotic prescribing decisions
Prazo: 28 days

Relative frequency with which result components and other factors are reported to influence antibiotic prescribing decisions

28 days

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

14 de dezembro de 2026

Conclusão Primária (Estimado)

14 de dezembro de 2027

Conclusão do estudo (Estimado)

14 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

23 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de novembro de 2026

Primeira postagem (Real)

17 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever